Condition: Prostate Cancer · Sponsor: Royal Marsden NHS Foundation Trust
DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.
This description comes directly from the study's public registry record.
Francesca Mason · +44 20 3186 5157 · mrltrials@rmh.nhs.uk
Sian Cooper · sian.cooper@rmh.nhs.uk
Always discuss trial participation with your own doctor first.
| Sunnybrook Health Sciences Centre | Toronto, Canada | Not Yet Recruiting |
| The Christie NHS Foundation Trust | Manchester, United Kingdom | Recruiting |
| The Royal Marsden NHS Foundation Trust | Sutton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06638541